The Safety and Tolerability Profile of Vilazodone, A Novel Antidepressant for the Treatment of Major Depressive Disorder
Vilazodone 40 mg/day was well tolerated during short- and long-term MDD treatment in these trials. Safety profiles associated with 8- and 52-week exposure were consistent.
Authors
- Harry A. Croft
- Μαρία Αθανασίου (ORCID: https://orcid.org/0000-0003-1575-9100)
- Michael R. Liebowitz (ORCID: https://orcid.org/0000-0002-8990-8845)
- Susan Gallipoli
- Carol R. Reed (ORCID: https://orcid.org/0000-0003-0143-4153)
- Heidi Whalen
- Daniel K. Kajdasz
Institutions
- New York State Department of State (US)
Publication Details
- Journal
- Psychopharmacology Bulletin
- Published
- 2025-08-12
- DOI
- https://doi.org/10.64719/pb.4075
- Citations
- 10
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00